Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Science 37 Hldgs Inc (SNCE)

Science 37 Hldgs Inc (SNCE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,327
  • Shares Outstanding, K 5,970
  • Annual Sales, $ 70,150 K
  • Annual Income, $ -50,990 K
  • EBIT $ -77 M
  • EBITDA $ -59 M
  • 60-Month Beta 0.55
  • Price/Sales 0.56
  • Price/Cash Flow N/A
  • Price/Book 0.66
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -10.40
  • Most Recent Earnings $-1.00 on 11/07/23
  • Next Earnings Date 03/18/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -3.80
  • Growth Rate Est. (year over year) +26,389.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.68 +1.23%
on 02/21/24
5.75 unch
on 03/11/24
+0.07 (+1.23%)
since 02/09/24
3-Month
3.73 +54.16%
on 12/21/23
7.39 -22.19%
on 12/26/23
+1.41 (+32.49%)
since 12/11/23
52-Week
3.73 +54.16%
on 12/21/23
12.96 -55.63%
on 08/10/23
+0.97 (+20.24%)
since 03/10/23

Most Recent Stories

More News
Science 37 Contributes Significantly to GSK's Phase 3 Rare Disease Trial Enrollment for Cholestatic Pruritus Treatment

Science 37 facilitated significant U.S. enrollment in a Phase 3 trial for cholestatic pruritus, enhancing patient access through remote participation.Quiver AI SummaryScience 37, a leader in improving...

SNCE : 5.75 (+0.35%)
Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial

SNCE : 5.75 (+0.35%)
Science 37 Reports Second Quarter 2022 Financial Results

RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”) the Agile Clinical Trial...

SNCE : 5.75 (+0.35%)
OpenSesame Appoints Tamar Elkeles, PhD, and Emily Rollins to its Board of Directors

OpenSesame today announced it has appointed Tamar Elkeles, PhD, and Emily Rollins to its Board of Directors. Dr. Elkeles is a highly regarded Chief Human Resources Officer and thought leader, advising...

GPX : 20.85 (unch)
GGGVU : 10.08 (-1.37%)
DLB : 77.62 (+0.43%)
XMTR : 42.12 (+1.08%)
SNCE : 5.75 (+0.35%)
Science 37 to Report Second Quarter 2022 Financial Results on August 11, 2022

RESEARCH TRIANGLE PARK, N.C., July 28, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™...

SNCE : 5.75 (+0.35%)
Oncology Clinical Trial Execs to Increase Decentralization, Science 37 Survey Indicates

Almost three in four (73%) oncology research executives plan to execute either a fully decentralized or hybrid clinical trial in the next 12 months...

SNCE : 5.75 (+0.35%)
Science 37® to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., June 07, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™,...

SNCE : 5.75 (+0.35%)
Science 37® to Present at the William Blair 42nd Annual Growth Stock Conference

RESEARCH TRIANGLE PARK, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™,...

SNCE : 5.75 (+0.35%)
Science 37 Introduces Virtual Site Model to Rescue Slow Enrolling Clinical Trials

New offering provides access to patients beyond the existing site network can be implemented in four weeks....

SNCE : 5.75 (+0.35%)
Science 37® Extends Leadership in Decentralized Clinical Trial Market with NextGen SaaS Release to Fully Orchestrate Decentralized Study Conduct

New release sets the bar as the most comprehensive platform to orchestrate decentralized study conduct—unifying stakeholder journeys, increasing...

SNCE : 5.75 (+0.35%)

Business Summary

Science 37 Inc. provides operating system for agile clinical trials. Science 37 Inc., formerly known as LifeSci Acquisition II Corp., is based in LOS ANGELES.

See More

Key Turning Points

3rd Resistance Point 5.78
2nd Resistance Point 5.76
1st Resistance Point 5.76
Last Price 5.75
1st Support Level 5.74
2nd Support Level 5.72
3rd Support Level 5.72

See More

52-Week High 12.96
Fibonacci 61.8% 9.43
Fibonacci 50% 8.35
Fibonacci 38.2% 7.26
Last Price 5.75
52-Week Low 3.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar